Silihan lan utang jangka dawa perusahaan Pharming (PHAR)

Pharming Group N.V. (PHAR) generates revenue from exclusive drugs for the therapy of rare immune pathologies, relying on multi-year patent protection. The business possesses full pricing power due to its monopoly in the field of recombinant protein synthesis. Dependence on external purification plants is mitigated by long-term contracts, and the indicator stands at 0.11. This chart illustrates the company's price action and quote dynamics.

Assessing the financial stability of Pharming Group N.V. (PHAR) requires an analysis of liabilities with maturities exceeding one year, which determine the cost of servicing leverage and the risk of liquidity gaps. By analyzing the business's long-term debt metrics, an investor can discern the balance between debt load and investments in the therapeutic protein platform, which ensures high margins due to its monopoly position in rare disease niches.